Miles
This article was originally published in The Tan Sheet
Executive Summary
Acquires 28.3% of generic drug company Schein for approximately $310 mil. Miles and Schein, which calls itself the "leading multisource pharmaceutical manufacturer" in the U.S., reported Feb. 17 that, under the strategic alliance, they will "analyze and identify potential areas of cooperation in product sourcing, production, distribution and marketing of current and future Schein and Miles products in the U.S. and abroad." Miles' agreement with Schein follows similar deals between Hoechst AG and Copley and between Marion Merrell Dow and Rugby
|
Acquires 28.3% of generic drug company Schein for approximately $310 mil. Miles and Schein, which calls itself the "leading multisource pharmaceutical manufacturer" in the U.S., reported Feb. 17 that, under the strategic alliance, they will "analyze and identify potential areas of cooperation in product sourcing, production, distribution and marketing of current and future Schein and Miles products in the U.S. and abroad." Miles' agreement with Schein follows similar deals between Hoechst AG and Copley and between Marion Merrell Dow and Rugby. |